News by Subject
News by Disease
News by Date
Post Your News
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
US & Canada
Post an Event
News | News By Subject | News by Disease |
News By Date | Search News
BioIndustry Association Release: Biomedical Catalyst to Re-Open on 29 July 2013
7/9/2013 10:58:42 AM
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
9 July 2013 -- The UK's innovation agency, the Technology Strategy Board's announcement today that the Biomedical Catalyst will reopen for applications for early- and late-stage awards on 29 July 2013 is welcome. The announcement follows a successful campaign and confirmation at the Spending Review of additional funding for the Technology Strategy Board.
The Biomedical Catalyst, launched as part of the government's Strategy for UK Life Sciences in December 2011, has been a major success. To date the government-backed Technology Strategy Board has funded more than 80 projects accelerating medical research and leveraging more than £55 million in additional private funding.
Steve Bates, BIA Chief Executive Officer, said:
"The BIA welcomes the Technology Strategy Board's decision to reopen the Biomedical Catalyst at the end of July. I know many companies are waiting for the opportunity to make applications. I encourage companies to prepare their applications as I am certain there will be strong demand once again."
Geoff Davison, Bionow Chief Executive Officer, said:
"Given the announcement of another round of this critical funding source, Bionow is keen to encourage more applications by companies across the UK. We will be working with partners to ensure that our members have every opportunity to apply for funding via this route."
Lin Bateson, BioPartner Executive Director, said:
"This announcement reinforces external perception of the UK's commitment to life science business growth, and will assist many future global collaborations."
Harriet Fear, One Nucleus Chief Executive, said:
"I'm delighted with the news, announced today by the Technology Strategy Board at the One Nucleus ON Helix Conference in Cambridge. Many of our members have benefitted from previous Biomedical Catalyst rounds and the difference it makes is significant."
For further information, please contact:
BIA: Robert Winder, Head of Communications, email@example.com, 020 7630 2191; mobile 07825 942 934.
Bionow: Geoff Davison, CEO, firstname.lastname@example.org, 07968 323381
BioPartner: Lin Bateson, Executive Director, email@example.com, 020 7193 7815
One Nucleus: Harriet Fear, CEO, firstname.lastname@example.org, 01223 896 454
The Biomedical Catalyst is a joint £180 million Technology Strategy Board and Medical Research Council programme which offers funding to innovative small and medium-sized enterprises (SMEs) and academics looking to work either individually or in collaboration to develop solutions to healthcare challenges.
BIA report on Biomedical Catalyst
BIA Biomedical Catalyst infographic
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry Association (BIA) is the trade association for innovative enterprises involved in UK bioscience. Members include emerging and more established bioscience companies; pharmaceutical companies; academic, research and philanthropic organisations; and service providers to the bioscience sector. The BIA represents the interests of its members to a broad section of stakeholders, from government and regulators to patient groups and the media. Our goal is to secure the UK's position as a global hub and as the best location for innovative research and commercialisation, enabling our world-leading research base to deliver healthcare solutions that can truly make a difference to people's lives. For further information, please go to www.bioindustry.org
Bionow is a not for profit membership organisation for the biomedical / life-sciences industry in the North of England and supports business growth, competitiveness and innovation. Our membership base includes start-ups and early stage firms as well as established growth-oriented companies. Bionow's membership offering focuses upon the specific needs of firms at their different stages of development, including dedicated business support programmes, shared procurement schemes with significant cost savings, exclusive insurance benefits, recruitment and training services, local and national events and access to a vibrant network of businesses. Website: www.bionow.co.uk
BioPartner is an independent, accredited trade organisation, promoting international partnering for trade, investment and collaborations with UK Life Science companies. BioPartner's delegations promote the UK presence at major international biopharma conferences. Through the BioPartnership Programme, BioPartner assists companies to attend these events by providing access to government grants and heavily discounted entry fees. www.biopartner.co.uk
Established in May 2010, One Nucleus is the result of the merger of ERBI and London Biotechnology Network. One Nucleus is a not-for-profit membership organisation for international life science and healthcare companies and the largest of its kind in Europe. The company is based in Cambridge UK and London, at the heart of Europe's largest cluster. The 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial Service Providers. Website: www.onenucleus.com
The Technology Strategy Board
The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org
Help employers find you! Check out all the jobs and post your resume.